192 related articles for article (PubMed ID: 8833207)
1. Interleukin-6 and tumor necrosis factor alpha levels after bisphosphonates treatment in vitro and in patients with malignancy.
Sauty A; Pecherstorfer M; Zimmer-Roth I; Fioroni P; Juillerat L; Markert M; Ludwig H; Leuenberger P; Burckhardt P; Thiebaud D
Bone; 1996 Feb; 18(2):133-9. PubMed ID: 8833207
[TBL] [Abstract][Full Text] [Related]
2. An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates.
Thiébaud D; Sauty A; Burckhardt P; Leuenberger P; Sitzler L; Green JR; Kandra A; Zieschang J; Ibarra de Palacios P
Calcif Tissue Int; 1997 Nov; 61(5):386-92. PubMed ID: 9351880
[TBL] [Abstract][Full Text] [Related]
3. Effect of first treatment with aminobisphosphonates pamidronate and ibandronate on circulating lymphocyte subpopulations.
Pecherstorfer M; Jilch R; Sauty A; Horn E; Keck AV; Zimmer-Roth I; Thiebaud D
J Bone Miner Res; 2000 Jan; 15(1):147-54. PubMed ID: 10646124
[TBL] [Abstract][Full Text] [Related]
4. Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and beta 2-microglobulin in multiple myeloma.
Terpos E; Viniou N; de la Fuente J; Meletis J; Voskaridou E; Karkantaris C; Vaiopoulos G; Palermos J; Yataganas X; Goldman JM; Rahemtulla A
Eur J Haematol; 2003 Jan; 70(1):34-42. PubMed ID: 12631257
[TBL] [Abstract][Full Text] [Related]
5. A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy.
Purohit OP; Radstone CR; Anthony C; Kanis JA; Coleman RE
Br J Cancer; 1995 Nov; 72(5):1289-93. PubMed ID: 7577484
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy.
Vinholes J; Guo CY; Purohit OP; Eastell R; Coleman RE
J Clin Oncol; 1997 Jan; 15(1):131-8. PubMed ID: 8996134
[TBL] [Abstract][Full Text] [Related]
7. Current and future directions in medical therapy: hypercalcemia.
Body JJ
Cancer; 2000 Jun; 88(12 Suppl):3054-8. PubMed ID: 10898351
[TBL] [Abstract][Full Text] [Related]
8. Bisphosphonates and breast carcinoma.
Lipton A
Cancer; 1997 Oct; 80(8 Suppl):1668-73. PubMed ID: 9362434
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-6 and the acute phase response during treatment of patients with Paget's disease with the nitrogen-containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate.
Schweitzer DH; Oostendorp-van de Ruit M; Van der Pluijm G; Löwik CW; Papapoulos SE
J Bone Miner Res; 1995 Jun; 10(6):956-62. PubMed ID: 7572320
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease.
Jagdev SP; Purohit P; Heatley S; Herling C; Coleman RE
Ann Oncol; 2001 Oct; 12(10):1433-8. PubMed ID: 11762816
[TBL] [Abstract][Full Text] [Related]
11. Bisphosphonates for cancer patients: why, how, and when?
Body JJ; Mancini I
Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
[TBL] [Abstract][Full Text] [Related]
12. Acute effects of pamidronate administration on serum levels of interleukin-6 in advanced solid tumour patients with bone metastases and their possible implications in the immunotherapy of cancer with interleukin-2.
Lissoni P; Cazzaniga M; Barni S; Perego MS; Brivio F; Fumagalli L; Tancini G
Eur J Cancer; 1997 Feb; 33(2):304-6. PubMed ID: 9135506
[TBL] [Abstract][Full Text] [Related]
13. Paget's disease of bone: benefits of neridonate as a first treatment and in cases of relapse after clodronate.
Filipponi P; Cristallini S; Policani G; Casciari C; Gregorio F
Bone; 1998 Dec; 23(6):543-8. PubMed ID: 9855463
[TBL] [Abstract][Full Text] [Related]
14. Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy.
Pecherstorfer M; Herrmann Z; Body JJ; Manegold C; Degardin M; Clemens MR; Thürlimann B; Tubiana-Hulin M; Steinhauer EU; van Eijkeren M; Huss HJ; Thiébaud D
J Clin Oncol; 1996 Jan; 14(1):268-76. PubMed ID: 8558208
[TBL] [Abstract][Full Text] [Related]
15. Effect of liposomal and free bisphosphonates on the IL-1 beta, IL-6 and TNF alpha secretion from RAW 264 cells in vitro.
Pennanen N; Lapinjoki S; Urtti A; Mönkkönen J
Pharm Res; 1995 Jun; 12(6):916-22. PubMed ID: 7667201
[TBL] [Abstract][Full Text] [Related]
16. Acute effects of intravenous administration of pamidronate in patients with osteoporosis.
Lim MJ; Kwon SR; Park SG; Park W
J Korean Med Sci; 2010 Sep; 25(9):1277-83. PubMed ID: 20808669
[TBL] [Abstract][Full Text] [Related]
17. Comparative tolerability of drug therapies for hypercalcaemia of malignancy.
Zojer N; Keck AV; Pecherstorfer M
Drug Saf; 1999 Nov; 21(5):389-406. PubMed ID: 10554053
[TBL] [Abstract][Full Text] [Related]
18. Pamidronate increases markers of bone formation in patients with multiple myeloma in plateau phase under interferon-alpha treatment.
Terpos E; Palermos J; Viniou N; Vaiopoulos G; Meletis J; Yataganas X
Calcif Tissue Int; 2001 May; 68(5):285-90. PubMed ID: 11683535
[TBL] [Abstract][Full Text] [Related]
19. In vitro toxicity of bisphosphonates on human neuroblastoma cell lines.
Vorotnjak M; Boos J; Lanvers-Kaminsky C
Anticancer Drugs; 2004 Sep; 15(8):795-802. PubMed ID: 15494642
[TBL] [Abstract][Full Text] [Related]
20. Ibandronate.
Dooley M; Balfour JA
Drugs; 1999 Jan; 57(1):101-8; discussion 109-10. PubMed ID: 9951955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
